Skip to main content

An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination with Low-Dose Ruxolitinib or Itacitinib Alone following Ruxolitinib in Subjects with Myelofibrosis

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

May 18, 2018

End Date

November 10, 2020
 

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

May 18, 2018

End Date

November 10, 2020